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Positron-emission-tomography (PET) imaging of tau pathology has facilitated
development of anti-tau therapies. While members of the arylquinoline and pyridoindole
families have been the most frequently used tau radioligands so far, analyses of their
comparative performance in vivo are scantly documented. Here, we conducted a head-
to-head PET comparison of the arylquinoline 18FT807 and the pyridoindole 18FTHK5117
PET in a mouse model of tau pathology. PET recordings were obtained in groups
of (N = 5–7) P301S and wild-type (WT) mice at 6 and 9 months of age. Volume-of-
interest based analysis (standard-uptake-value ratio, SUVR) was used to calculate effect
sizes (Cohen’s d) for each tracer and age. Statistical parametric mapping (SPM) was
used to assess regional similarity (dice coefficient) of tracer binding alterations for the
two tracers. Immunohistochemistry staining of neurofibrillary tangles was performed for
validation ex vivo. Significantly elevated 18F-T807 binding in the brainstem of P301S
mice was already evident at 6 months (+14%, p < 0.01, d = 1.64), and increased
further at 9 months (+23%, p < 0.001, d = 2.70). 18F-THK5117 indicated weaker
increases and effect sizes at 6 months (+5%, p < 0.05, d = 1.07) and 9 months (+10%,
p < 0.001, d = 1.49). Regional similarity of binding of the two tracers was high (71%)
at 9 months. 18F-T807 was more sensitive than 18F-THK5117 to tau pathology in this
model, although both tracers present certain obstacles, which need to be considered in
the design of longitudinal preclinical tau imaging studies.
Keywords: tau, small animal PET, transgenic mice, 18F-T807, 18F-THK5117
INTRODUCTION
Neurofibrillary tangles constitute one of the most characteristic neuropathological findings in
Alzheimer’s disease (AD), which is the most frequent form of dementia, and likewise occur in
certain non-AD forms of dementia known as tauopathies (Duyckaerts et al., 2009). Whereas AD is
characterized by paired helical filaments containing equal amounts of 3R and 4R isoforms, non-AD
tauopathies present with other tau ultrastructures and isoforms. For example, the pathology in
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progressive supranuclear palsy and corticobasal degeneration
consists of 4R tau aggregating into straight filaments (Murray
et al., 2014). The recent development of 18F-fluorinated
radioligands for positron-emission-tomography (PET) studies
of tau aggregates intensely accelerated research in the field of
tau imaging in AD and non-AD tauopathies (Villemagne and
Okamura, 2016). Members of the arylquinoline and pyridoindole
structural families have been the most frequently used tau
radioligands to date. Although tau PET has been hindered due
to off-target binding of ligands to neuromelanin (Hansen et al.,
2016) and MAO-B (Ng et al., 2017), both tracer classes can
differentiate AD and non-AD tauopathy patients from healthy
controls.
Small animal PET (µPET) has emerged as a useful
tool for translational research involving in vivo imaging of
β-amyloid and neuroinflammation markers in rodent models of
neurodegenerative diseases (Zimmer et al., 2014; Brendel et al.,
2015; Liu et al., 2015). However, there have been relatively
few tau-PET studies in wild-type (WT) and transgenic mice
(Maruyama et al., 2013; Okamura et al., 2013), due in part
to concerns about the sensitivity of tau ligands for species-
dependent isoforms and intracellular compartmentation of tau
aggregates. We previously characterized the performance of
µPET with the arylquinoline 18F-THK5117 in two transgenic
mouse models of tau pathology (Brendel et al., 2016); this
tracer showed elevated brain uptake in both types of model
mice relative to WT mice, and brain uptake patterns correlated
with autoradiography and immunohistochemistry findings of
tau deposition. Nonetheless, the sensitivity of 18F-THK5117
was rather low, with a detection threshold of 10% tau/area,
and quantitation was degraded by spillover from extracerebral
structures compounded by rapid washout from brain.
In light of the previous findings, further research is needed
to improve preclinical imaging of tau pathology in mouse
models. Thus, the aim of the current µPET study was to
compare representative members of the two major classes of tau
radioligands with regard to their ability to track longitudinally the
expression of tau pathology in the brain of P301S transgenic mice.
MATERIALS AND METHODS
Radiochemistry
Radiosynthesis of the pyridoindole 18F-T807 was performed as
previously described (Gao et al., 2015), with modifications for
a fully automated preparation on Neptis perform module1 as
specified in the Supplementary Methods. A radiochemical yield
of>20% was achieved, with chemical and radiochemical (HPLC)
purities of >98%. The 18F-T807 was directly used for µPET with
a specific activity of >216 GBq/µmol at the end of synthesis.
Radiosynthesis of 18F-THK5117 was performed as previously
described (Tago et al., 2014), with slight modifications as
specified in the Supplementary Methods. The procedure
yielded a radiochemical purity >98% and specific activity of
202± 56 GBq/µmol at the end of synthesis.
1http://www.neptis-vsa.com/
Animals and Study Design
All experiments were carried out in compliance with the German
national guidelines for animal protection (TierSchG, Germany)
and approval of the local animal care committee (Regierung von
Oberbayern), with supervision by a veterinarian. Animals were
housed in a temperature- and humidity-controlled environment
with a 12-h light–dark cycle, with free access to food (Ssniff, Soest,
Germany) and water.
Tau-P301S (P301S) transgenic (TG) mice were investigated in
this study together with age-matched WT controls. P301S mice
express human P301S mutant 4R/0N tau (Thy1-hTau.P301S) in
CBA.C57BL/6 background (Allen et al., 2002). This model is
characterized by predominant tau hyperphosphorylation in the
brainstem, where tau filaments appear mostly as half-twisted
ribbons. Larger paired helical tau filaments reminiscent of those
seen in human AD are observed less frequently. The behavioral
phenotype manifests as learning deficits from 2 to 3 months of
age, and onset of motor impairment at 4 months, leading to early
death before 12 months of age. Eight P301S mice and eight age-
matched C57Bl/6 littermates serving as controls were included in
the study. Imaging with dual tracers was performed at baseline (at
6 months of age) and at follow-up (at 9 months of age). Maximum
time span between paired measurements was 10 days.
Tau PET
Data Acquisition and Analyses
For details of data acquisition and reconstruction see
Supplementary Methods. In brief, summed 5–65 min dynamic
emission frames for each tracer (18F-T807 and 18F-THK5117)
were co-registered to an MRI mouse brain atlas (Dorr et al.,
2007) after frame-wise correction for motion using the PMOD
fusion tool (V3.5, PMOD Technologies Ltd.). The reader
was blind to the type of mouse. A second experienced reader
ensured accurate alignment of the fusion image and corrected if
necessary. Volumes-of interest (VOI) were defined on the MRI
mouse atlas (Figure 1).
Due to progressively increasing bone labeling with 18F-T807
scan duration, we modified our previously published brainstem
VOI (Brendel et al., 2016) by reducing its width and increasing
its length, so as to reduce signal spill-in from extra-cerebral
structures near the ovoid VOI (11 mm3). Bone uptake was
obtained from a bilateral VOI in the petrous bone (9 mm3)
and uptake in the bilarteral Harderian glands was also measured
(40 mm3). A whole brain VOI was applied to measure the
radiotracer uptake in the entire brain (525 mm3). The cerebellum,
with exclusion of voxels of the cerebellar peduncle (volume
56 mm3), which was the optimal reference VOI identified for
18F-THK5117, (Brendel et al., 2016), proved to be vulnerable to
spill-in from the extensive bone uptake occurung in the 18F-T807
scans. Therefore we used the bilateral striata together with the
septum (volume 38 mm3) as the reference tissue VOI, which
was unaffected by cranial spill-in from 18F-T807, and is not
reported to contain tau deposition in P301S mice (Allen et al.,
2002). To enable direct comparisons of both tracers using the
same reference region, we performed additional analyses with
modified striatal and cerebellar reference regions, which are
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FIGURE 1 | Definition of VOIs projected on the mouse brain MRI atlas (Dorr
et al., 2007) in sagittal and coronal slices: (A) Oval-shaped brainstem VOI
including central parts of the pons and the midbrain (middle row; 11 mm3; red
line). (B) Spherical striatal reference VOI (top row; 38 mm3; green line).
(C) Crescent-shaped cerebellar reference VOI (top row; 56 mm3; blue line).
presented in the Supplementary Material. Time-activity-curves of
brainstem, striatum, cerebellum, Harderian glands, and petrous
bone were extracted from the dynamic emission sequences.
Brainstem and reference VOIs were employed for calculation of
the mean brainstem-to-striatum ratio for 18F-T807 (40–60 min,
SUVRBST/STR) and the brainstem-to-cerebellum 18F-THK5117
(30–60 min, SUVRBST/CBL), where SUVR is the standardized
uptake value ratio. A reader-independent coregistration was
established after validation of the optimal time window by
stability analysis of ratio TACs in the emission sequence for each
tracer. Further details are provided in Supplementary Methods.
Statistical Parametric Mapping (SPM)
For whole-brain voxel-wise comparisons of the two tau
tracers, SPM was performed using SPM5 routines (Wellcome
Department of Cognitive Neurology, London, United Kingdom)
implemented in MATLAB (version 7.1) (Rominger et al., 2013).
SUVR images were scaled by the tracer-specific reference region
before statistical analysis.
Immunohistochemistry
After completion of the final µPET scans, mice were killed
by cervical dislocation, and the brains rapidly removed. After
fixation by immersion overnight in 4% paraformaldehyde
at 4◦C, brains were post-fixed in phosphate buffered saline.
Two representative 50 µm thick slices per animal were cut
in the sagittal plane using a vibratome (VT 1000 S, Leica,
Wetzlar, Germany). Free-floating sections were permeabilized
with 2% Triton X-100 overnight and blocked with I-BlockTM
Protein-Based Blocking Reagent (Thermo Fischer Scientific).
We obtained immunohistochemical labeling of microtubule-
associated protein tau (MAPT) using PA5-27287 primary
antibody (Invitrogen, dilution 1:400) – recognizing amino
acids 1 – 286 of human Tau and the A-21244 secondary
antibody (Invitrogen, 1:500). The unbound dye was removed
by three washing steps with PBS, and the slices were then
mounted on microscope slides with fluorescent mounting
medium (Dako, Germany). Images were acquired with a LSM
780 confocal microscope (Zeiss) equipped with a 40×/1.4
oil immersion objective. The excitation wavelength was
633 nm and emission was detected from 650 to 758 nm.
For each brain slice 3-dimensional 16 bit data stacks of
10240 pixels × 9216 pixels × 67 pixels were acquired from the
brainstem (area matching the VOI of PET) at a lateral resolution
of 0.35 µm/pixel and an axial resolution of 1.0 µm/pixel. Whole
brain overview images were obtained by two-dimensional
acquisition.
To quantify tau volume load, we employed custom-
written Matlab software. Local background subtraction was
used to diminish intensity variations among different stacks.
Subsequently, MAPT was identified by applying the 80th
percentile as minimal intensity threshold. Noise was excluded by
applying a connected component analysis excluding patches of
contiguous voxels smaller than 1 µm. Within this tau 3D mask
contiguous patches with a minimum diameter of 3 µm in all
spatial directions were considered as tau-positive somata. These
analyses were performed by an operator who was blind to the
µPET results.
Statistics
Group comparisons of VOI-based PET results between TG and
WT mice (baseline and follow-up) were assessed by an unpaired
Student’s t-test using IBM SPSS Statistics (version 23.0; SPSS,
Chicago, IL, United States). Longitudinal data were compared
between baseline and follow-up by a paired Student’s t-test.
A threshold of p < 0.05 was considered to be significant for
rejection of the null hypothesis.
RESULTS
Overview
One P301S and one WT mouse died before the first PET scan.
Two P301S mice had to be euthanized after the follow-up 18F-
T807 scan due to poor health and did not receive the second 18F-
THK5117 scan. Resulting final animal numbers and PET SUVR
results by group are presented in Table 1.
Comparison of Tracer Characteristics
Head-to-head comparison of the TACs indicated a faster tracer
washout of 18F-THK5117 from whole brain when compared
to 18F-T807. Relative to the mean peak activity, 57% remained
at 10 min and 11% remained at 60 min after 18F-THK5117
injection, while 72% remained at 10 min and 26% at 60 min
after 18F-T807 injection (both contrasts p < 0.001; Figure 2A).
Radioactivity uptake in the petrous bone relative to the whole
brain uptake was 42% higher for 18F-T807 than 18F-THK5117
(p < 0.001) at 10 min post injection (p.i.), and +164% higher
at 60 min p.i. (p < 0.001) (Figure 2B). 18F-THK5117 uptake
in the Harderian glands relative to the whole brain significantly
exceeded that for 18F-T807 after 15 min p.i. (+15%, p < 0.05),
with a widening gap between the two tracers until 60 min p.i.
(+32%, p < 0.001) (Figure 2C). A previously reported frontal
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cortex hotspot (Brendel et al., 2016) was evident in 31% of
18F-THK5117 SUVR images, but was absent in all 18F-T807
scans.
Dynamic Tau Imaging
TAC ratios (SUVRBST/STR) for 18F-T807 stabilized after
30 min p.i. in baseline and follow-up scans, with the 40–
60 min p.i. interval period giving the best discrimination
between P301S and WT mice at 6 and 9 months of
age (Figures 3A,B). TAC ratios (SUVRBST/CBL) of 18F-
THK5117 also stabilized after 30 min p.i. for baseline
and follow-up time scans, but the 30–60 min period p.i.
gave the best discrimination between P301S and WT mice
(Figures 3C,D).
VOI and SPM Analyses of Static SUVR
Images
18F-T807 indicated significantly higher uptake in the brainstem
VOI of P301S mice when compared to WT mice at baseline
(+14%, p < 0.01) and follow-up PET scanning (+23%,
p < 0.001). Brainstem uptake of 18F-THK5117 was slightly
elevated at baseline (+5%, p < 0.05) in the same contrast,
and increased further at follow-up (+10%, p < 0.05). Effect
sizes were distinctly higher for 18F-T807 brainstem uptake
when compared to 18F-THK5117 at both scanning ages
(Figure 4A). Utilization of the same reference regions resulted
in a loss of the significant results for 18F-T807 when the
modified cerebellum was used, and for 18F-THK5117 when
the modified striatum was used (see Supplementary Results).
The modified cerebellar reference region appeared to be
generally less affected by bone uptake for 18F-T807, but the
substantial bone uptake in some animals distinctly increased the
variance and made group results unreliable. Even a modified
striatal VOI degraded the otherwise significant results for 18F-
THK5117, most likely due to hot spot noted above. SPM
congruently showed higher T-scores for baseline and follow-
up contrasts of 18F-T807 in comparison to 18F-THK5117
(Figures 4B,C). A comparison of T-score maps of both tau
ligands (P301S vs. WT; 9 months) indicated a high dice similarity
of 71%.
TABLE 1 | Demographics and result overview.
PET session Age
(months)
SUVR
P301S
SUVR WT Effect size
(d)
BL 18F-T807 6 1.11± 0.07∗∗ 0.97± 0.09 1.64
(N = 7) (N = 7)
FU 18F-T807 9 1.18± 0.04∗∗∗ 0.95± 0.07 2.70
(N = 7) (N = 7)
BL 18F-THK5117 6 1.11± 0.04∗ 1.06± 0.05 1.07
(N = 7) (N = 7)
FU 18F-THK5117 9 1.16± 0.05∗∗∗ 1.06± 0.09 1.49
(N = 5) (N = 7)
BL, baseline; FU, follow-up. P301S versus WT: ∗p < 0.05; ∗∗p < 0.01;
∗∗∗p < 0.001; d, Cohen’s d.
FIGURE 2 | Comparison of 18F-T807 and 18F-THK5117 wash-out from brain
(A) and uptake in adjacent extracerebral structures (B: Petrous bone; C:
Harderian glands).
Longitudinal Imaging of Tau Pathology in
P301S Mice
Longitudinal increases in SUVR between baseline and follow-up
scanning in P301S mice were 5.9± 4.5% for 18F-T807 (p < 0.05)
and 4.7± 4.4% for 18F-THK5117 [p = not significant (n.s.)]. SPM
indicated comparable longitudinal changes in the brainstem of
P301S mice by both tracers. (Figures 5C,D). WT mice did not
show any longitudinal changes in SUVR for either tracer.
Immunohistochemical Validation
P301S mice revealed tau-positive staining predominantly in the
brainstem, and penetrating into the cerebellar peduncles, with
lesser amounts in the forebrain, and complete absence in the
cerebellar hemispheres, as previously demonstrated (Brendel
et al., 2016). Similarly, the striatum did not indicate any
tau deposition to immunohistochemistry. The tau burden was
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FIGURE 3 | Curves of ratios over time derived from dynamic PET imaging of 18F-T807 (A,B) and 18F-THK5117 (C,D). Red lines/squares show transgenic P301S
mice and black lines/circles indicate WT mice. Each point is the mean of 5–7 measurements, with error bars indicating SD.
15.4 ± 1.5% per volume in the brainstem by the new 3-
dimensional approach. %-tau positively correlated with SUVR
of 18F-T807 (R = 0.68, p = 0.21) and SUVR of 18F-THK5117
(R = 0.42, p = 0.48), although these associations did not reach
significance (Figure 6).
DISCUSSION
This is to our knowledge the first longitudinal small animal PET
study of tau distribution in a transgenic mouse model of tau
pathology, comprising an in vivo comparison of representatives
of the two currently most frequently used tau PET tracers.
Quantitation of the pyridoindole ligand 18F-T807 and the
arylquinoline ligand 18F-THK5117 present specific obstacles for
preclinical PET imaging, arising from the substantial uptake
in bone and Harderian glands, resulting in signal spill-in,
compounded by especially fast washout of brain signal from
18F-THK5117. In addition, we again observed the inexplicable
accumulation of 18F-THK5117 at the frontal pole of some mice,
irrespective of the genotype. Despite these issues, the current
data provide compelling evidence that longitudinal preclinical
PET imaging of tau pathology in P301S mice is feasible with
both radioligands. We found moderately superior sensitivity of
18F-T807 for the contrast of P301S versus age-matched WT
mice, compared to 18F-THK5117. Voxel-wise analysis of the
age-dependent increases in SUVR in P301S mice indicated high
regional similarity for the two ligands, suggesting that they are
both sensitive to tau accumulation in the brainstem.
Head to Head Comparison of 18F-T807
and 18F-THK5117
A strength of this study lies in the head-to-head dual tau tracer
assessment in the same animals examined within a span of only
a few days. By this approach, we were able to directly compare
18F-T807 and 18F-THK5117 labeling of tau pathology in the
brainstem of P301S mice at two different ages. Higher effect
sizes were observed with 18F-T807 for baseline and follow-up
comparisons of P301S versus WT groups. Thus, considering
results of the baseline scans, the detection threshold of tau
burden (%/area) in the brainstem of P301S mice is evidently
lower for 18F-T807 than for 18F-THK5117. This is in accord
with results of a recent study showing higher sensitivity for
18F-AV-1451 in a head-to-head comparison 18F-THK5351 by
PET imaging of AD patients in vivo (Jang et al., 2017). As
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FIGURE 4 | (A) Bar graphs show group mean SUVRs of P301S (red) and WT
(gray) mice for baseline and follow-up PET measurements of 18F-T807 and
18F-THK5117. Error bars indicate SD, effect sizes are given by Cohen’s d.
Sagittal slices (median and 0.6 mm paramedian) show voxel-wise statistical
parametric mapping (SPM) between transgenic P301S and WT mice at
baseline (BL) and follow-up (FU) for 18F-T807 (B) and 18F-THK5117 (C).
SPM-maps are depicted upon a MRI mouse atlas and extracerebral voxels
are masked. The t-score threshold of 2 complies a significance threshold of
0.01 uncorrected.
histological tau burden is already present at the age of 6 months
in these mice (Brendel et al., 2016), it seems that both ligands
are practically insensitive to early tau deposition in the rodent
brain. A limitation of our comparison lies in the impossibility
of using exactly the same reference region for both tracers.
While reasons for this difficulty are discussed below, we are
convinced that using the optimal reference tissue for either tracer
is a valid approach. Both reference tissues were lacking in tau
pathology to immunohistochemical analyses, which substantiates
their suitability, despite the lack of a single region optimal for
both tracers. In general, the signal of both radioligands was
only moderately increased (versus WT) at the follow-up PET
scan at 9 months of age, despite the very heavy tau burden in
the brainstem of P301S mice at this age (14–18%). The lower
histological tau concentrations in the frontal cortex were not
detected by either PET ligand irrespective of the TG mouse
age. In this regard, present results are consistent with our
previous 18F-THK5117 investigation in the same TG mouse
model (Brendel et al., 2016), although we note that percentages of
the newly developed 3-dimensional approach fell distinctly below
the earlier 2-dimensional immunohistological assessment. This
is surely related to overlay effects arrising from a 2-dimensional
acquisition, were several cell layers are summed in the calculation
(illustrated in Figures 6B–D).
There is still some controversy about the specificity of
pyridoindole and arylquinoline ligands for non-AD tau, with
conflicting findings reported in vivo and in vitro (Chiotis
et al., 2016; Ishiki et al., 2016; Smith et al., 2016). Aged
P301S mice contain 4R tau, mainly occurring in a half-twisted
ribbon conformation typical of human frontotemporal dementia,
but they also express paired-helical filaments similar to those
occurring in AD (Allen et al., 2002). Although both radioligand
classes showed binding to 4R non-AD tau in brain of patients
with corticobasal degeneration or progressive supranuclear palsy
in vivo (Josephs et al., 2016; Hammes et al., 2017; Smith et al.,
2017), and likewise to post mortem examination (Josephs et al.,
2016; Kikuchi et al., 2016), other studies did not find significant
binding in 4R-tauopathies, e.g., using 18F-T807 (Coakeley et al.,
2016; Marquie et al., 2017). The ultrastructure of tau as expressed
in P301S mice might not be perfectly suited for high affinity
binding by 18F-T807 and 18F-THK5117. This issue will only be
circumvented if sensitive and specific ligands for the 4R form of
tau are developed. For the present, translational comparisions
between tracer binding to tau in mice and humans should be
interpreted with caution as tau ultrastructures in mouse models
only partially match the human pathology.
We have also evaluated the arylquinoline 18F-THK5351 in
mouse models of tau pathology and WT mice. However, 18F-
THK5351 proved to have such rapid kinetics in mouse brain
that specific tau signal in brain was overwhelmed by spill-in
from extra-cerebral regions (see Supplementary Results). Thus,
we elected to use the previsously evaluated arylquinoline18F-
THK5117 for the current study.
Challenges of Preclinical Tau PET
Bone uptake is more pronounced for 18F-T807 than to 18F-
THK5117 (Figure 2), but extracerebral binding must be taken
into consideration when planning the target and reference region
of preclinical tau PET studies with either of these ligands. In
general, bone labeling is indicative of hepatic defluorination of
the tracer, which is often more pronounced in rodents than in
humans or non-human primates. Present results suggest that
tracking of mouse cortical tau pathology may be favored with 18F-
THK5117, due to the less contribution of signal spill-in than from
18F-T807. On the other hand, imaging of tau in the frontal pole of
the cortex is problematic for 18F-THK5117 due to spill-over from
the Harderian glands, and the still inexplicable hot-spot signal in
about one third of mice with C57Bl/6 background, irrespective of
their transgenic status. Mice of other backgrounds do not seem to
be affected by the latter phenomenon (Brendel et al., 2016). The
current brainstem target region (in the modified version) did not
indicate clear advantages or disadvantages for one or the other
of the ligands, although we chose in the present study to alter
its shape so as to better avoid spill-over from the petrosal bone,
which is pronounced in the case of 18F-T807 µPET.
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FIGURE 5 | Longitudinal findings of SUVR for (A)18F-T807 and (B) 18F-THK5117 in individual WT and TG mice. Red lines represent SUVR of individual P301S mice
at baseline and follow-up scanning. WT mice are presented in gray by group mean (solid) ± SD (dotted). Sagittal (0.6 mm paramedian) and coronal (pons/midbrain
junction) slices show voxel-wise results of longitudinal statistical parametric mapping (SPM) showing regions with significantly increased tau ligand binding in
transgenic P301S mice (C: 18F-T807; D: 18F-THK5117). SPM-maps are projected upon a MRI mouse atlas and extracerebral voxels are masked. The t-score
threshold of 1 complies a significance threshold of 0.05 uncorrected.
FIGURE 6 | (A) PET-Immunohistochemistry correlation of 18F-T807 (blue diamonds) and 18F-THK5117 (yellow circles) SUVR with %tau/area to PA5-27287 antibody
staining. (B) 3-dimensional brainstem acquisition of PA5-27287 staining and (C) zoomed image indicating automatically detected tau positive cell somata.
(D) 2-dimensional whole brain overview shows tau-positive cells predominantly in the brainstem, and lower amounts in the neocortex. Data derive from N = 5 P301S
mice.
Another difficulty presented by tau PET with the arylquinoline
18F-THK5351 and also the pyridoindole 18F-T807 is off-target
binding to monoamine oxidases (MAO) A or B (Vermeiren et al.,
2015; Ng et al., 2017). A recent study has also indicated off-target
binding of 18F-THK5117 to MAO-B in brain (Lemoine et al.,
2017), which might have been predicted from structural motifs.
However, the contribution of MAO to the 18F-THK5117 binding
signal in mouse brain remains to be established. Additional
in vivo blocking experiments by MAO inhibitors were not
possible in the present cohort due to the high rate of drop-
outs expected for aged TG exposed to additional scanning
sessions. Thus, we cannot presently exclude a contribution of
MAO binding to the present findings with 18F-T807 and 18F-
THK5117 PET, although we note that the immunohistochemical
findings support our attribution of the PET results mainly to
tau deposition. Most relevantly, MAO can be elevated as part
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of inflammatory responses in the course of neurodegenerative
diseases (Carter et al., 2012). If parts of the tracer signal in our
tau model indeed belongs to MAO binding, it will be necessary
to separate the binding components by pharmacological blocking
studies, or in double TG mice with knockout of MAO A or B.
Due to the configuration of our animal holder, we are unable
to obtain blood samples during the recording. This introduces
some variance due to individual differences in tracer metabolism,
although our use of SUVR values should largely compensate for
such factors.
Longitudinal Imaging
Present data give a first demonstration of the value of longitudinal
µPET imaging in tau transgenic models. The phenotype of
mouse models of neurodegenerative diseases is well-known to
show considerable heterogeneity, as seen in the present study
from the different baseline SUVR results of P301S mice for
both tau tracers in Figure 5. By recording the kinetics of tau
deposition in individual animals it should in future studies
be feasible to minimize possible biasing effects of differing
pathological trajectories depending on baseline differences. This
scenario is reminiscent of our earlier preclinical findings with
amyloid-PET, whereby individual responses to an anti-amyloid
treatment proved to be dependent on the amyloidosis at baseline
(Brendel et al., 2015). Thus, PET imaging of P301S mice
can be translationally used to monitor anti-tau drugs during
preclinical evaluation and this data will potentially lead to a better
understanding of tau-PET monitoring in humans. As a limitation
we note that longitudinal increases of MAO could as well lead to
a elevated PET signal due to off-target binding, however, recent
data in AD suggests different time courses for astrocytosis and
tau protein deposition (Scholl et al., 2015).
CONCLUSION
Longitudinal µPET imaging of tau pathology is feasible in
a preclinical setting using P301S mice. Analysis of brainstem
uptake showed 18F-T807 to be moderately superior to 18F-
THK5117 regarding sensitivity for preclinical tau imaging. The
two tracers, which represent distinct structural classes, both suffer
from particular shortcomings in the present mouse model, which
must be considered in the design of longitudinal studies of tau
deposition.
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